Management of aromatase inhibitor-induced musculoskeletal symptoms

Arjun Gupta, N. Lynn Henry, Charles L. Loprinzi

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole. Musculoskeletal symptoms can severely affect patients' quality of life and also lead to premature discontinuation of aromatase inhibitor therapy. Several interventions for managing AIMSS have been investigated in the last decade, with some demonstrating promise. This article provides an evidence-based summary to guide practicing oncologists in regard to the epidemiology, prevention, and treatment of AIMSS.

Original languageEnglish (US)
Pages (from-to)733-739
Number of pages7
JournalJCO Oncology Practice
Issue number11
StatePublished - Nov 2020

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)


Dive into the research topics of 'Management of aromatase inhibitor-induced musculoskeletal symptoms'. Together they form a unique fingerprint.

Cite this